Breast

NICE Backs Use Of Drugs For Breast Cancer Prevention

(PharmaTimes [UK]) Mar 23, 2017 - The National Institute for Health and Care Excellence has now published updated familial breast cancer guidelines which advocate the use of three medicines to reduce the risk of developing the disease.

read article

Amgen Targets Roche in Europe With Herceptin Biosimilar Submission

(BioPharma Reporter) Mar 22, 2017 - Amgen has signalled its intention to take a share of the $6.9bn Herceptin market by filing its trastuzumab candidate in the EU.

read article

9 Deaths Are Linked to Rare Cancer From Breast Implants

(New York Times) Mar 21, 2017 - A rare cancer first linked to breast implants in 2011 has now been associated with nine deaths, the Food and Drug Administration said Tuesday.

read article

Eating Soy Does Not Seem To Be A Problem For Women With Breast Cancer

(Washington Post) Mar 20, 2017 - A study finds soy consumption linked to lower risk of death from all causes.

read article (free registration required)

If You’ve Avoided Colonoscopies Because Of The Icky Prep, Help May Be On The Way

(Washington Post) Mar 18, 2017 - Tasty shakes are part of an effort to make lifesaving screening less onerous.

read article (free registration required)

Radiotherapy Risks Are Much Higher for Smokers

(Cancer Research UK) Mar 20, 2017 - Smokers treated for breast cancer have much higher risks than non-smokers of developing lung cancer or heart attack as a result of radiotherapy - according to a new study funded by Cancer Research UK and published today in the Journal of Clinical Oncology.

read press release

Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy

(Yahoo! Finance) March 20, 2017 - Genomic Health, Inc. today announced results from 15 Oncotype DX Breast Recurrence Score® studies conducted in 12 countries that provide real-world evidence of the test's ability to change treatment decisions in breast cancer patients.

read article

Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival

(Lilly) Mar 20, 2017 - Eli Lilly and Company today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer who have relapsed or progressed after endocrine therapy.

read corporate press release

Lilly's Breast Cancer Drug Combination Succeeds Key Study

(Reuters) Mar 20, 2017 - Eli Lilly and Co said a combination of its experimental breast cancer drug and another widely used treatment slowed disease progression in a key study in patients who had relapsed or did not derive enough benefit from anti-estrogen therapy.

read article

ASCO Guidelines on Adjuvant Bisphosphonates in Breast Cancer

(Medscape Medical News) Mar 15, 2017 - The use of two bisphosphonates as adjuvant therapy should be considered for all postmenopausal women with early breast cancer who are deemed to be candidates for adjuvant therapy, according to a new joint clinical practice guideline from Cancer Care Ontario and the American Society of Clinical Oncology (ASCO).

read article (free registration required)

Yale Study Published in JNCCN Uncovers Racial Disparities in Treatment of Women with Breast Cancer

(NCCN) Mar 15, 2017 - Researchers at Yale Cancer Center/Smilow Cancer Hospital found that black and Hispanic women in Connecticut are significantly less likely to undergo gene expression profiling than white women.

read press release

Researchers Find Evidence-Based Radiation Treatment After Lumpectomy Leads to High-Quality, High-Value Care for Patients

(ASCO) Mar 14, 2017 - A new study demonstrates that the use of less radiation therapy (RT) for breast cancer patients who have undergone lumpectomy does not negatively impact patient outcomes, and could result in significant reductions in health care costs.

read press release

TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer

(TapImmune) Mar 14, 2017 - TapImmune, Inc. today announced that its collaborators at the Mayo Clinic, recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on TapImmune’s HER2/neu-targeted T-cell vaccine that will enroll women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS).

read corporate press release

Finding Positive In The Negative

(Mass General) Mar 14, 2017 - Novel antibody-drug conjugate shows promising results in patients with advanced triple-negative breast cancer.

read press release

FDA OKs New Novartis Drug For Type of Advanced Breast Cancer

(ABC News/Associated Press) Mar 13, 2017 - U.S. regulators have approved a new drug as an initial treatment for postmenopausal women with a type of advanced breast cancer.

read article

New Class of Cancer Drugs Might Have a Broader Market Than Anticipated

(STAT Plus) Mar 13, 2017 - One in five women with breast cancer could be treated effectively with PARP inhibitors, according to a new study published Monday in Nature Medicine.

read article (paid subscription required)

FDA Approves Kisqali for Breast Cancer Subset

(CureToday.com) Mar 13, 2017 - Kisqali (ribociclib), a CDK 4/6 inhibitor, gained approval from the Food and Drug Administration (FDA) for the frontline treatment of postmenopausal women with hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

read article

What a Genome-Wide Screening Can Reveal about Cancer Survival

(Berkeley Lab) Mar 13, 2017 - What if a simple genetic test could tell cancer patients what their odds of survival are? It’s an approach that researchers at the Department of Energy’s Lawrence Berkeley National Laboratory are developing, and they have made significant inroads in several types of cancer, most recently for breast cancer.

read article

One in Five Breast Cancer Patients Could Benefit From Existing Treatment, Genetic Study Reveals

(Wellcome Trust Sanger Institute [UK]) Mar 13, 2017 - Researchers have discovered that a greater number of breast cancers are genetically similar to rarer cases with faulty BRCA1 or BRCA2 genes.

read article

Novartis Kisqali® (ribociclib, LEE011) Receives FDA Approval as First-Line Treatment for HR+/HER2-Metastatic Breast Cancer in Combination With any Aromatase Inhibitor

(Novartis) Mar 13, 2017 - The US Food and Drug Administration (FDA) has approved Kisqali® (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.

read corporate press release
Next Page